title: The AcrySof Toric intraocular lens in subjects with cataracts and corneal astigmatism: a randomized, subject-masked, parallel-group, 1-year study.
abstract: OBJECTIVE
  To compare the AcrySof Toric intraocular lens (IOL) and an AcrySof spherical control IOL and to investigate rotational stability of the AcrySof Toric IOL (Alcon Laboratories, Inc., Fort Worth, TX) in subjects with cataracts and preexisting corneal astigmatism.
  
  
  METHODS
  Randomized, subject-masked, parallel-group, multicenter, 1-year study.
  
  
  METHODS
  We included 517 subjects (Toric IOL, n = 256; control IOL, n = 261).
  
  
  METHODS
  Unilateral implantation of an AcrySof Toric or AcrySof spherical control IOL (spherical powers, 12.00-25.00 diopters [D]; cylinder powers 1.50, 2.25, or 3.00 D for corneal astigmatism correction of 0.75 to < 1.50, ≥ 1.50 to <2.00, and ≥ 2.00 D with no upper limit, respectively). No limbal relaxing incisions were permitted.
  
  
  METHODS
  Visual acuity outcomes, IOL position, patient-reported spectacle use, and safety.
  
  
  RESULTS
  One year postoperatively, best spectacle-corrected distance visual acuity of ≥ 20/20 was 77.7% (Toric IOL) versus 69.2% (control IOL). Uncorrected distance visual acuity of 20/20 or better was 40.7% (Toric IOL) versus 19.4% (control IOL; P<0.05). Mean absolute residual refractive cylinder was 0.59 D (Toric IOL) versus 1.22 D (control IOL; P<0.0001). Mean rotation was < 4° (range, 0°-20°) for the Toric IOL. Six-month spectacle freedom was 61.0% (Toric IOL) and 36.4% (control IOL; P < 0.0001). Complications in both groups were few and were as would be expected with cataract surgery.
  
  
  CONCLUSIONS
  Favorable efficacy, rotational stability, distance vision spectacle freedom, and safety results support the use of the AcrySof Toric IOL for patients with cataracts and corneal astigmatism.
  
  
  BACKGROUND
  Proprietary or commercial disclosure may be found after the references.
authors.affiliation: Cincinnati Eye Institute, University of Cincinnati, Cincinnati, Ohio, USA. eholland@fuse.net
authors.forename: Edward
authors.initials: E
authors.lastname: Holland
authors.forename: Stephen
authors.initials: S
authors.lastname: Lane
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Horn
authors.forename: Paul
authors.initials: P
authors.lastname: Ernest
authors.forename: Robert
authors.initials: R
authors.lastname: Arleo
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Miller
mesh_terms: D000180:Acrylic Resins; D000368:Aged; D001251:Astigmatism / Q000503:physiopathology / Q000601:surgery*; D002386:Cataract / Q000628:therapy*; D004311:Double-Blind Method; D005139:Eyeglasses / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007431:Intraoperative Complications; D019654:Lens Implantation, Intraocular; D007910:Lenses, Intraocular; D008297:Male; D018918:Phacoemulsification; D011183:Postoperative Complications; D019591:Pseudophakia / Q000503:physiopathology*; D016896:Treatment Outcome; D014786:Vision Disorders / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000180:Acrylic Resins